3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Liquidia and its subsidiary Liquidia Technologies signed a settlement agreement with United Therapeutics on October 13, 2026, resolving all pending litigation between the companies. Liquidia will keep marketing YUTREPIA for pulmonary arterial hypertension but must remove the PH-ILD indication from the label and stop promoting it for that use, and it must make payments totaling a stated net $380.7 million in 2026 and 2027.
Net payment to United Therapeutics of $175.0 million due within 30 business days, plus $145.4 million in two $72.7 million installments due January 31, 2027 and April 30, 2027
Separate settlements with Sandoz, Henderson and PBM total about $60.3 million; the PBM agreement is with a related party that is controlled by a director, and the board's disinterested members approved it
Lender consent for a letter of credit tied to the settlement raised the minimum cash covenant under the revenue interest financing agreement from $15.0 million to $45.0 million
Preliminary, unaudited third-quarter 2026 YUTREPIA net product sales were $222.7 million, and cash and cash equivalents were $396.1 million as of September 30, 2026
Pioneer Acquisition I Corp, a blank check company listed on Nasdaq, entered into a Business Combination Agreement on October 6, 2026 with Green AI Cloud, Inc., a Stockholm-based AI data center company. If completed, Green AI Cloud would become a wholly owned subsidiary of Pioneer, and its shareholders would receive 30,000,000 shares of Pioneer common stock, plus up to 5,000,000 earn-out shares. The deal requires approval by Pioneer shareholders and is expected to close in the second quarter of 2027.
Green AI Cloud is valued at a pre-money equity value of $300 million; the Aggregate Consideration is 30,000,000 shares at $10.00 per share.
Up to 5,000,000 earn-out shares ($50 million at $10.00 per share) vest in three tranches based on 2027–2029 EBITDA targets or share prices of $11.00–$13.00.
Pioneer will redomicile from the Cayman Islands to Delaware before the merger; the deal is expected to close in the second quarter of 2027.
The agreement has a business combination deadline of June 20, 2027, and Pioneer's public shareholders may elect to have their shares redeemed.
On October 13, 2026, Biomea Fusion reported topline Phase 1 GLP-131 results for BMF-650, its investigational oral GLP-1 receptor agonist. In Cohorts 1-4, mean Day 29 weight reduction ranged from 1.5% to 3.2% versus 0.1% for pooled placebo, and the company reported no severe or serious adverse events among active-dose participants, but the results are preliminary, the sample sizes are small, and the company says longer-term toxicology studies are still needed before further development, which may include a partnership.
Cohorts 1-4 (outpatient): mean Day 29 weight reduction of 1.5% to 3.2% versus 0.1% for pooled placebo.
Cohort 5 (under confinement, 200 mg then 400 mg): 6.1% (6.2 kg) mean weight reduction at Day 29; the company says it should be interpreted separately because confinement appeared to affect eating behavior.
No severe or serious TEAEs, TEAE-related dose modifications, or TEAE-related discontinuations across the 40 active-dose MAD participants; nausea occurred in 17.5% and vomiting in 7.5% across active cohorts.
Longer-term toxicology studies are required; the company is positioning BMF-650 for a strategic partnership, which could include licensing, while its primary focus remains icovamenib.
On October 12, 2026, VisionWave agreed with Sadot Group and others to terminate the September 30 joint venture, after CM said it could not produce the financial statements the agreement required. Sadot's funding commitment of up to $7,814,323 was extinguished without any amount being funded, and no termination penalty is payable. VisionWave keeps 250,000 Sadot shares and will issue 500,000 of its own common shares to Sadot, while it also takes on indemnification obligations to Sadot.
Letter Agreement dated October 12, 2026 terminated the JV Agreement signed September 30, 2026 with Sadot Group Inc. and CMJV LLC
Sadot's Capital Commitment of up to $7,814,323 was terminated and none of it was funded; no early termination penalty or break fee is payable
VisionWave will issue 500,000 shares of common stock to Sadot within three business days and retains 250,000 Sadot Entry Premium Shares
VisionWave, VisionWave Israel and CMJV jointly and severally agreed to indemnify Sadot against losses tied to the CM Rights and related matters
Dot Ai (CID HoldCo, Inc.) closed its acquisition of Envoy Technologies, Inc. on October 9, 2026, making Envoy a wholly owned subsidiary. The deal was paid in Dot Ai common stock and Series C Preferred Stock, valued at about $65.0 million at a $6.00 reference price, and it is expected to leave BladeRanger holding a majority of Dot Ai's common stock on an as-converted basis once conversions are completed, which would dilute existing shareholders. The company believes it now meets Nasdaq's $2.5 million stockholders' equity requirement, but its continued listing remains subject to the Nasdaq Hearings Panel's confirmation.
Closed October 9, 2026; BladeRanger received 233,543 common shares and 8,433,123 Series C Preferred Shares at closing
Blink Charging holds a $12,500,000 Envoy convertible note that will convert into 2,166,667 common shares upon stockholder approval and an effective Form S-1 registration statement
Dot Ai believes its stockholders' equity meets the $2.5 million Nasdaq minimum; the Nasdaq Hearings Panel must confirm
Parties agreed to use reasonable best efforts to obtain stockholder approval by January 31, 2027
Nasdaq's Hearings Panel decided on October 7, 2026, that CN Healthy Food Tech Group is in compliance and may remain listed, subject to conditions. The panel found the company failed to give Nasdaq and investors accurate information about its China Securities Regulatory Commission application, though it said the omission did not relate to finances or business operations.
Panel decision dated October 7, 2026; company may remain listed on Nasdaq
Company must keep remedial measures for three years from the panel decision date
One-year Discretionary Panel Monitor: any listing standard failure leads to a Staff Delisting Determination without a cure period
Company does not intend to seek Listing Council review; the council may still review on its own within 45 days
Polar Power's board approved a co-CEO structure under which Chris Mayer became Co-Chief Executive Officer effective October 6, 2026, while Arthur Sams continues as Co-CEO and President. Mayer will oversee corporate strategy, financial performance, investor relations and capital allocation, and Sams will oversee operations, and Mayer is also the managing member of CL Investment, an investor that holds the Company's securities and has a board designee.
Chris Mayer, age 30, appointed Co-CEO effective October 6, 2026, with no compensatory arrangement disclosed for his appointment.
Arthur Sams remains Co-CEO and President; his compensation will not change under the new structure.
Mayer controls CL Investment, which bought 833 Series A Convertible Preferred shares and warrants for 227,182 common shares on August 5, 2026, and a $82,500 convertible note for $75,000 on August 28, 2026.
The Company announced the structure in a press release dated October 12, 2026, citing growth opportunities in telecom, data centers and defense.
On October 13, 2026, Energy Fuels and the parties to the VAC acquisition merger agreement signed a First Amendment that addresses an ongoing customer dispute over a commercial supply agreement, possible settlement, repayment of certain debt, and possible purchase price adjustments. The 8-K also includes VAC's 2025 audited financial statements, which show lower revenue and continued losses, and discloses the planned departure of Energy Fuels' Chief Legal Officer.
Merger Agreement Amendment dated October 13, 2026 covers a customer dispute, possible settlement, debt repayment and potential purchase price adjustments.
VAC (Ara VAC IE Aggregator, LP) revenue was EUR 325.1 million in 2025, down from EUR 353.5 million in 2024.
VAC reported a loss after tax of EUR 87.9 million in 2025, compared with a loss of EUR 96.8 million in 2024.
Energy Fuels disclosed the planned departure of its Chief Legal Officer and Executive Vice President, Global Government Relations; the filing does not name the executive.
The SEC declared effective the Form S-4 registration statement for the proposed business combination between Agility Robotics and Churchill Capital Corp XI (Nasdaq: CCXI) on October 13, 2026. Churchill XI has set an extraordinary general meeting of shareholders for November 2, 2026 to vote on the deal, which is expected to close in November 2026 and would list the combined company on Nasdaq as AGLT.
SEC declared the S-4 registration statement effective on October 13, 2026; it was originally filed September 4, 2026.
Churchill XI shareholder meeting set for November 2, 2026 at 9:00 a.m. Eastern Time.
Expected gross proceeds above $620 million, including about $424 million in trust (assuming no redemptions) and about $200 million from a PIPE led by Foxconn.
Closing expected in November 2026; the combined company would trade as AGLT.
Copley Acquisition Corp and Ignite Proteomics mutually agreed on October 9, 2026 to terminate their June 10, 2026 Business Combination Agreement. Copley says it intends to keep pursuing a business combination and has until November 2, 2026 to complete one, subject to extension under its organizational documents.
Business Combination Agreement with Ignite Proteomics, signed June 10, 2026, was terminated by mutual agreement on October 9, 2026.
Each party bears its own expenses, and the agreement includes mutual releases of claims tied to the terminated deal.
Copley's deadline to complete a business combination is November 2, 2026, subject to extension.
Filing warns Copley may have to redeem public shares and liquidate its trust account if it cannot complete another deal.
Porch Group and Porch Insurance Reciprocal Exchange agreed on October 13, 2026 to acquire Allied Trust's insurance carrier and managing general agency, with the carrier purchase at a $55 million cash base price plus $50 million of deferred consideration. The company expects the deal to add approximately $200 million of Reciprocal Written Premium and $25 million of Adjusted EBITDA (Excluding Reciprocal) in the first full year after closing, but the transaction requires regulatory approvals and is expected to close in the first quarter of 2027.
Carrier purchase: $55 million in cash base price, plus $50 million deferred consideration payable over the 12 months after closing in cash or PRCH shares
Managing general agency and captive reinsurance entity: $95 million aggregate base price, including $75 million in cash and an expected $20 million in PRCH shares
Expected first-full-year contribution: approximately $200 million Reciprocal Written Premium and $25 million Adjusted EBITDA (Excluding Reciprocal); Porch cites an acquisition multiple of less than four times
Closing expected in Q1 2027, subject to regulatory approvals including Texas Department of Insurance; Porch plans to file an at-the-market equity offering program
Equus Total Return, Inc. was notified by the NYSE on October 6, 2026, that its common stock fell below the $1.00 minimum average closing price over 30 consecutive trading days. The notice is a deficiency notice, not a delisting, and the stock continues to trade on the NYSE for now. Shareholders should note the company plans to cure the deficiency within a six-month period, with a reverse stock split among the options it is considering.
NYSE notice dated October 6, 2026 cites Section 802.01C: average closing price below $1.00 over 30 consecutive trading days
Company plans to notify the NYSE by October 20, 2026 of its intent to cure the deficiency
Cure period is six months from receipt of the notice; a reverse stock split is among the alternatives under consideration
Common stock continues to trade on the NYSE; the company said the notice does not affect its operations or SEC reporting
Minerals Technologies completed a $400 million offering of 7.500% Senior Notes due 2032 and amended its credit agreement with JPMorgan Chase Bank as administrative agent. The company plans to use the note proceeds, plus cash on hand, to redeem its outstanding 5.000% senior notes due 2028 and pay offering fees. The amendment replaces the existing $400 million revolving facility with a $500 million facility maturing October 13, 2031.
$400 million of 7.500% Senior Notes due 2032, interest payable January 15 and July 15 starting January 15, 2027
Proceeds, with cash on hand, to redeem all outstanding 5.000% senior notes due 2028 and pay fees
New $500 million senior secured revolving credit facility maturing October 13, 2031, replacing the $400 million revolver
Existing $564.9 million senior secured term loan facility is not changed and matures November 26, 2031
Park Dental Partners disclosed that unauthorized access to its network in August 2026 led to data being acquired, including patients' protected health information, and it is completing notifications under state and federal law. Four putative class actions have been filed in Minnesota state court, and the company says it has not identified any material impact on its financial condition or results to date.
Unauthorized network access identified on August 28, 2026; law enforcement notified
Four putative class actions filed in Ramsey County, Minnesota; first filed September 3, 2026
Plaintiffs moved on October 7, 2026 to consolidate the actions and appoint interim lead class counsel
No material impact on financial condition or results identified to date, including expected legal and advisor costs
After the FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, Revolution Medicines borrowed a $250.0 million Tranche A loan from Royalty Pharma under a senior secured facility. The company also chose not to sell a Tranche 3 revenue participation right, which would have brought in up to $250.0 million, so it will not receive that payment.
Tranche A loan of $250.0 million advanced on October 8, 2026, with a $5.0 million draw fee paid to the lender.
Interest is three-month Term SOFR (3.50% floor) plus 5.75%, paid quarterly; the loan is interest-only and matures October 8, 2032.
Prepayment carries a make-whole amount plus a 3.0% premium before October 8, 2028, and smaller premiums afterward.
The company did not deliver a Tranche 3 Notice by October 10, 2026, forgoing a Tranche 3 Purchase Price of up to $250.0 million.
On October 6, 2026, Third Coast Bancshares entered into an agreement to acquire Great Plains Bancshares, parent of Great Plains National Bank in Elk City, Oklahoma, through a two-step merger in which Great Plains shares convert into Third Coast common stock. The deal requires approval from shareholders of both companies, regulatory approvals and the effectiveness of a Form S-4, and it would increase the number of Third Coast shares outstanding.
Agreement dated October 6, 2026; Great Plains shareholders holding about 27.6% of Great Plains stock signed a voting agreement to support the merger.
Exchange ratio equals 5,570,352 divided by Great Plains shares outstanding at closing, and is reduced if Great Plains delivers less than $153,300,000 of adjusted capital, surplus and retained earnings.
Great Plains would pay a termination fee of $11,981,827 in certain circumstances, including those involving alternative acquisition proposals.
Either party may terminate if the merger is not completed by September 30, 2027; the Company is to add two directors, Todd Taylor and Paul M. Dickinson, to its board at closing.
STERIS, through subsidiary STERIS Corporation, agreed on October 11, 2026 to acquire Xodus Medical, a Pennsylvania specialty surgical products business, for $2.1 billion in cash at closing, with up to $150 million more tied to calendar 2028 performance targets. The deal is expected to be financed mainly with debt, backed by a $2.0 billion bridge financing commitment, and is expected to close by December 31, 2026, subject to regulatory approvals.
Cash price: $2.1 billion at closing, subject to customary adjustments, plus up to $150 million in earnout tied to calendar 2028 targets
Financing: expected to be funded primarily with debt; $2.0 billion senior unsecured bridge facility from JPMorgan Chase Bank and Goldman Sachs Bank USA
Timing: expected to close by December 31, 2026; either party may terminate if not closed by July 12, 2027, extendable to January 11, 2028
AZZ reported second-quarter fiscal 2027 sales of $486.9 million, up 16.7%, and adjusted diluted EPS of $2.00, up 29.0%, for the quarter ended August 31, 2026. GAAP diluted EPS fell 34.2% to $1.94 because the prior-year quarter included a large AVAIL joint venture gain, and the company raised its fiscal 2027 guidance for sales, adjusted EBITDA and adjusted diluted EPS.
Second-quarter sales were $486.9 million; Metal Coatings rose 22.9% to $233.5 million and Precoat Metals rose 11.5% to $253.4 million.
GAAP diluted EPS was $1.94, down 34.2%; adjusted diluted EPS was $2.00, up 29.0%.
Fiscal 2027 adjusted diluted EPS guidance was raised to $7.00-$7.30 from $6.75-$7.15, and sales guidance to $1.825-$1.875 billion from $1.80-$1.85 billion.
During the first half, AZZ repurchased $20.0 million of common stock and completed the $57.5 million Seattle Galvanizing acquisition.
On September 30, 2026, Interactive Strength exchanged $7,685,090 of outstanding convertible note obligations for 768,509 shares of newly designated Series R Convertible Preferred Stock, and the notes were cancelled. On October 1, 2026, subsidiary Wattbike refinanced its working capital facility with up to £1,375,000 (about $1,825,200) of new term, invoice discounting and inventory financing, with lenders holding security over its assets. The Series R preferred ranks senior to common stock and is convertible into common, and the new loans include events of default that allow lenders to demand immediate repayment.
September 30, 2026: $7,685,090 of remainder notes exchanged for 768,509 Series R Preferred shares; company to reimburse holders $50,000 in legal fees
October 1, 2026: Wattbike prior facility repaid in full, with a £85,000 (about $112,800) exit fee and new financing of up to £1,375,000 (about $1,825,200)
Inventory loan facility of up to £750,000 (about $995,600) carries interest of 1.85% per month and is secured by a debenture over all Wattbike assets
Series R Preferred ranks senior to common stock; 1,619,907 common shares were outstanding as of September 30, 2026
SAIC said Kenneth Crews, former Corporate Vice President and CFO of Northrop Grumman, will become Executive Vice President and Chief Financial Officer effective December 7, 2026, after joining as CFO-elect on October 30, 2026. Prabu Natarajan, the current CFO, will become permanent Executive Vice President of the Civilian Business Group and will cease being CFO as of the effective date.
Kenneth (Ken) Crews, age 45, joins October 30, 2026 as CFO-elect and assumes the CFO role December 7, 2026
Crews' annual base salary is $740,000, with a short-term incentive cash bonus target of 100% of base salary
Crews receives a one-time sign-on cash payment of $250,000 and a sign-on RSU award with a $2,000,000 grant date value
Prabu Natarajan becomes permanent Executive Vice President, Civilian Business Group, and continues as Executive Vice President of Enterprise Operations
Quantumsphere Acquisition Corp (QUMS), a special purpose acquisition company, entered into a merger agreement on October 9, 2026 with Fortune Favor Technology Inc., a provider of technology consulting and solutions for medical cold-chain transportation. The deal implies a pre-money equity value of about $600 million for Fortune Favor, and completion depends on shareholder approvals, an SEC registration statement and Nasdaq listing approval.
Agreement signed October 9, 2026; each Fortune Favor share is valued at $10.00 in Purchaser ordinary shares, based on a pre-money equity valuation of about $600 million
Each Quantumsphere ordinary share converts into one Purchaser ordinary share; each right converts into one-seventh of a Purchaser ordinary share
Sponsor Whiteowl Holdings LLC and certain Fortune Favor shareholders agreed to support support agreements; lock-up lasts 180 days after closing or until shares close at or above $12.50 for 20 of 30 trading days
Either party may terminate if the other causes a delay exceeding six months; a $500,000 break-up fee applies in certain cases
Niki BioSolutions appointed Thomas Freeburg as its Chief Financial Officer under an employment agreement, with the appointment effective September 1, 2026, for a two-year term that either party can end on 45 days' notice. The filing says his base salary is $250,000, with $25,000 of each monthly payment deferred until the company receives certain funding, and he is eligible for an annual bonus of up to 50% of base salary plus 50,000 stock options at $8.83 per share.
Board appointed Thomas Freeburg as CFO on October 9, 2026, effective as of September 1, 2026
Base salary of $250,000, rising to $275,000 upon receipt of additional company funding
Eligible for an annual bonus of up to 50% of base salary and 50,000 stock options priced at $8.83 per share
Freeburg previously served as CFO of Interpace Biosciences, Inc. from February 2021 through March 2023
Wheeler Real Estate Investment Trust entered into a Note Purchase Agreement on October 13, 2026, to issue promissory notes totaling up to $25 million in principal, with the initial note at $1 million. The notes carry 0.00% interest, mature 18 months after issuance, and require amortization payments that can be made in common stock, which could dilute existing shareholders, subject to stockholder approval and an effective registration statement.
Initial Note Investor purchase: $1,000,000 principal note; maximum aggregate principal of up to $25,000,000 across Notes.
Notes bear 0.00% interest and mature 18 months after issuance; amortization payment set at 0.4% of original principal per trading day, adjustable between 0.2% and 0.6%.
Amortization payments are paid in common stock at market value, or in cash if the price is below $0.25 per share or other listed conditions are not met.
Closing requires stockholder approval for issuance above 19.99% of outstanding common stock and an effective resale registration statement; purchase price is paid in Series D Preferred Stock at $25.00 liquidation preference.
Alaunos Therapeutics completed its merger with privately held Velaris Therapeutics on October 13, 2026, making Velaris a wholly owned subsidiary. A concurrent $350 million private placement is expected to close on October 14, 2026, and the filing says Velaris holders and the investors will receive large amounts of convertible preferred stock, which can convert into common shares and would dilute existing stockholders once converted.
Velaris holders received 105,286 Series B and 33,054 Series C non-voting convertible preferred shares, each convertible into 1,000 common shares, subject to conditions.
Private placement covers 687,789 common shares at $1.4357 per share and 243,063 Series C preferred shares at $1,435.70 per share, for an aggregate purchase price of approximately $350 million.
Stockholder meeting proposals include conversion approval, an authorized share increase, a name change to Velaris Therapeutics, a reverse stock split and a new equity plan; three directors are to resign upon conversion approval.
SSR Mining agreed on October 13, 2026 to acquire all outstanding shares of Roxmore Resources through a British Columbia plan of arrangement, paying C$6.75 per share in cash. The company said the cash component is funded from its current balance sheet and estimated the fully diluted equity value at about $464 million, with enterprise value of $392 million, excluding the value of a new spin-off company. The deal adds Roxmore's Converse gold project in Nevada, six kilometers from SSR's Marigold mine, which the company says could add about 150,000 to 170,000 ounces of annual gold production with initial capital of $800 million to $900 million.
Cash consideration of C$6.75 per Roxmore common share; estimated fully diluted equity value of about $464 million and enterprise value of $392 million, excluding SpinCo
Closing requires approval by at least 66 2/3% of votes cast by Roxmore securityholders, and the Supreme Court of British Columbia; the company expects completion in Q4 2026
Either party may terminate if closing has not occurred by April 13, 2027; Roxmore would owe a C$18.0 million termination fee in certain circumstances
Roxmore securityholders with about 26.8% of shares have agreed to vote in favor; SSR Mining will hold a 14.99% stake in SpinCo, which will receive US$10.0 million in funding
Bumble Inc. agreed on October 12, 2026 to be acquired by Ithaca Holdings in an all-cash deal valuing the company at $1.3 billion, with Class A shareholders receiving $6.05 per share, a premium of about 138% to the unaffected October 9, 2026 closing price. Stockholder written consent has already been delivered by the Principal Stockholders, so no further shareholder vote is required, and the company will not issue a third-quarter 2026 earnings release.
Class A common stock holders to receive $6.05 per share in cash, about 138% premium to the unaffected closing price on October 9, 2026
Company termination fee of $29 million may apply under certain circumstances; Ithaca Holdings would pay a $102 million parent termination fee in specified cases, to be deposited in escrow by October 19, 2026
Merger must close by July 12, 2027 or either party may terminate; the company will file its Form 10-Q for the third quarter by November 9, 2026 and will not hold an earnings call
Newton Golf Company received a Nasdaq Staff determination on October 6, 2026, that it has not shown compliance with the $2,500,000 minimum stockholders' equity requirement for continued listing. Unless the company requests an appeal by October 13, 2026, its common stock will be suspended at the opening of business on October 15, 2026, and delisted from Nasdaq.
Nasdaq Staff determination dated October 6, 2026 cites the $2,500,000 stockholders' equity minimum under Listing Rule 5550(b)(1)
Appeal request deadline is October 13, 2026; without it, trading suspension begins October 15, 2026
Company intends to request a hearing before a Nasdaq Hearings Panel, which would stay the suspension and delisting pending the Panel's decision
The filing states there is no assurance the Panel will grant continued listing
Skydance Corporation issued $11,983,970,000 in U.S. dollar second lien notes and EUR 546,547,000 in euro second lien notes on October 9, 2026, in exchange for existing notes issued by its WBD subsidiaries. The notes are secured by second-priority liens on substantially all personal property and rank junior to the company's credit facilities and first lien notes, so the exchange adds secured debt that sits ahead of unsecured obligations.
As of the October 6, 2026 expiration date, about 99.15% of the existing exchange offer notes were validly tendered, and about 98.83% of the existing tender offer notes were tendered for cash.
The notes are junior in lien priority to the company's credit facilities and first lien senior secured notes, and liens are released for a series if an Investment Grade Event occurs and the company has no more than $250,000,000 of term B lo
The filing also describes a warrant distribution with an issue date of October 13, 2026, and NYSE ticker SKYD WS, for holders of Class B common stock as of the October 5, 2026 record date.
Johnson & Johnson reported third-quarter 2026 sales up 5.9% to $25.4 billion, but net earnings fell 95.9% to $210 million after a one-time special charge for the proposed talc litigation resolution. Adjusted EPS fell 7.5% to $2.59, and the company raised its full-year 2026 adjusted EPS guidance midpoint to $11.10, which matters to shareholders because the higher outlook is offset by a large reported charge and lower adjusted profit.
Q3 2026 reported sales were $25,399 million, up 5.9% from $23,993 million; net earnings were $210 million versus $5,152 million, and diluted EPS was $0.09 versus $2.12.
Adjusted diluted EPS was $2.59 versus $2.80 a year earlier, down 7.5%.
Full-year 2026 adjusted EPS guidance midpoint rose to $11.10 from $11.04 in July 2026; estimated reported sales midpoint is $101.2 billion.
Other (income) expense, net was $5,780 million in the quarter, reflecting the talc litigation charge, the Firefly Bio acquisition and the Sail Biomedicines collaboration.
Mirum Pharmaceuticals announced topline results from the Phase 3 EXPAND study of Livmarli (maralixibat) in ultra-rare cholestatic liver diseases, saying the study met its primary endpoint. In the pediatric primary analysis, pruritus improved 1.81 points from baseline on maralixibat versus 0.83 points on placebo, and the company plans to submit a U.S. supplemental New Drug Application in the first half of 2027.
Primary endpoint: 1.81-point improvement on maralixibat vs. 0.83 on placebo, a placebo-adjusted difference of 0.98 points (p=0.0004)
Serum bile acids fell 70.1% on maralixibat vs. 3.5% on placebo, a 69.0% treatment effect (p<0.0001)
No new safety signals; diarrhea reported in 64.0% of maralixibat patients vs. 11.1% on placebo
Supplemental New Drug Application planned in the United States in the first half of 2027
GigCapital8 Corp. entered into a merger agreement under which its SPAC merger and a Quantisimo merger would make both companies wholly owned subsidiaries of a new publicly traded holding company, PubCo. The Quantisimo owners, WISeQey and SealSQ, would receive 66,610,000 PubCo shares, and completion depends on shareholder approvals and other closing conditions.
Merger agreement dated October 8, 2026, entered into October 9, 2026, per the filing
Company Shareholders to receive 66,610,000 PubCo shares, plus Company Cash Contribution Credit Shares at $10.00 per share
Minimum cash of $15,000,000 to be available to PubCo at closing
Sponsor to receive 3,035,083 PubCo Ordinary Shares and 3,035,084 Class F shares; Class F shares to hold 49.999999% of total votes
CDT Equity Inc. issued a $6,750,000 senior secured convertible note to J.J. Astor & Co. on October 6, 2026, to be funded in two tranches. The company received $3,000,000 in the first tranche and must repay the note in weekly installments starting October 14, 2026, with maturity on March 24, 2027. The lender can convert the note into common stock at a discounted price and received warrants for 225,000 shares, which could add shares outstanding for existing shareholders.
First tranche: $3,000,000 received against $4,050,000 of principal, with net proceeds of $2,869,850 after closing fees
Second tranche of $2,000,000 is subject to conditions on or before December 31, 2026, including a closing bid price of at least $3.00
Conversion price is the greater of 70% of the lowest closing price over 20 trading days or a $0.18354 floor; warrants for 225,000 shares at $0.9177
80% of net proceeds from the at-the-market offering with A.G.P. are applied to the note first; the note is secured by a first priority lien
Dauch Corporation said Nathan Iles will join as Senior Vice President of Finance on November 2, 2026, and will succeed Christopher May as Chief Financial Officer on December 1, 2026. May will move to Executive Vice President and Chief Administrative Officer, keeping IT and adding oversight of HR, and the filing says Terri Kemp will retire at the end of 2026.
Nathan Iles starts as Senior Vice President of Finance on November 2, 2026, and becomes CFO on December 1, 2026
Iles has been CFO of Standard Motor Products since 2019 and was previously CFO of UCI International Holdings from 2016 to 2019
Iles's offer letter sets a $650,000 base salary, a 100% target annual bonus and a 200% target long-term incentive
Christopher May becomes Executive Vice President and Chief Administrative Officer on December 1, 2026
Harmony Biosciences said CEO Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026, as part of a planned succession. Chief Operating Officer Peter Anastasiou will become President, Chief Executive Officer and a Class I director on January 1, 2027, and the company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
Dayno retires as President and CEO and steps down from the board on December 31, 2026, and will serve as a non-executive advisor through 2027.
Anastasiou, COO since April 2026, becomes President and CEO effective January 1, 2027, and joins the board as a Class I director.
The company reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
Harmony still expects to report multiple ascending dose study data for BP-205 in Q4 2026.
For the 12 weeks ended September 12, 2026, net sales and other revenue fell 0.1% to $18,894.7 million and identical sales declined 0.8%. Net income dropped to $51.5 million, or $0.11 per share, from $168.5 million, or $0.30 per share, a year earlier. The company no longer provides a fiscal 2026 outlook and will launch a comprehensive business review, with an updated outlook expected by its fourth quarter earnings call.
Net income of $51.5 million, or $0.11 per share, versus $168.5 million, or $0.30 per share, in the second quarter of fiscal 2025
Adjusted net income of $179.0 million, or $0.36 per share, versus $248.4 million, or $0.44 per share; Adjusted EBITDA of $784.0 million versus $848.4 million
No fiscal 2026 outlook; a refreshed financial framework is expected with the turnaround plan by the fourth quarter earnings call
Quarterly dividend of $0.17 per share to be paid November 6, 2026 to holders of record as of October 23, 2026
On October 9, 2026, Kenvue entered a Third Supplemental Indenture amending the indenture for its existing senior notes. The changes are tied to Kimberly-Clark's exchange offers and consent solicitations, which cover up to $7 billion principal amount of notes, and would remove most restrictive covenants, certain default triggers, the SEC reporting covenant, and limits on mergers and asset transfers. The amendments take effect only at settlement of the exchange offers, which is expected on or about the closing of Kimberly-Clark's acquisition of Kenvue.
Third Supplemental Indenture dated October 9, 2026, amends the indenture covering seven series of existing Kenvue senior notes, maturing 2028 through 2063.
Kimberly-Clark's exchange offers cover up to $7,000,000,000 aggregate principal amount of Kimberly-Clark notes plus cash.
Amendments become operative only upon settlement, expected on or about the closing of Kimberly-Clark's acquisition of Kenvue.
Event-of-default provisions for failure to pay principal, premium or interest are not eliminated by the amendments.
BK Technologies disclosed that a severe thunderstorm caused a partial roof collapse at its West Melbourne, Florida headquarters and main industrial facility on October 8, 2026, after business hours, with no employees injured. The company expects temporary effects on production of BKR 9000 radios, BKR 9500 production-readiness activities and radio repair services, and it has not yet estimated the impact on its previously announced financial outlook.
Partial roof collapse at West Melbourne, Florida facility on October 8, 2026, during a severe thunderstorm; no employees were injured
Water damage reported in the server room, production area and customer service area; IT systems at the facility were disrupted
Company has started its disaster recovery procedures and an insurance claims process covering business interruption and other losses, subject to policy terms
Company is evaluating the effect on its outlook but cannot yet reasonably estimate magnitude or timing
Xponential Fitness's board adopted a limited-duration stockholder rights plan that becomes exercisable if a person or group acquires 19.9% or more of Class A shares. The company said the plan aims to prevent a large accumulation of shares that could hurt trading, and that it will not block an acquisition but encourages bidders to negotiate with the board first. The board's strategic alternatives review, with Jefferies as financial advisor, remains ongoing.
Rights are issued to holders of record as of October 22, 2026, and expire October 11, 2027 unless redeemed earlier.
Rights become exercisable only if a person or group acquires 19.9% or more of outstanding shares; exercise price is $15.00 per Unit.
The company may redeem the rights for $0.001 per right before they become exercisable.
The filing says the strategic alternatives review led by independent directors remains ongoing, with Jefferies as financial advisor.
Mueller Water Products said Chief Financial Officer Melissa Rasmussen will step down, with the change taking effect the first business day after the company files its 10-K for the fiscal year ended September 30, 2026. Mike Morgan, currently CFO of IvyTree Holdings LLC, was appointed Executive Vice President, Finance, effective October 28, 2026, and will become Executive Vice President and CFO at the transition date. The filing states the departure is not the result of any disagreement over financial statements, internal controls, operations, policies or practices.
Melissa Rasmussen steps down as Senior Vice President and CFO; she will serve as Senior Advisor through December 31, 2026.
Mike Morgan, age 56, was appointed Executive Vice President, Finance, effective October 28, 2026, and will become CFO at the transition date (the press release says on or about November 19, 2026).
Morgan's offer letter provides a $575,000 base salary, an 80% target bonus, a $1,300,000 target long-term incentive from fiscal 2027, and a $700,000 sign-on bonus.
Rasmussen's transition agreement provides a $431,897 retention payment and a fiscal 2026 bonus based on actual performance, subject to a release of claims.
Avery Dennison said its board elected Helen Sheirbon, currently senior vice president and chief operating officer of Global HP Solutions at HP Inc., as president of its Solutions Group, effective November 3, 2026. The filing sets a base salary of $625,000 and special equity and cash awards, which shareholders can review as part of the company's executive pay disclosure.
Sheirbon's role is effective November 3, 2026; the board elected her on October 9, 2026
Base salary of $625,000, with target annual incentive of 60% and target long-term incentive of 200% of base salary
One-time awards include $2,000,000 in restricted stock units, $1,500,000 in performance units, a $250,000 signing bonus and an $800,000 cash payment in February 2027
On October 9, 2026, a federal court temporarily barred Corteva and EIDP from paying dividends or repurchasing shares, and from disposing of assets outside the ordinary course of business, in litigation filed by 15 states and one sovereign over the Corteva and Vylor separation. On October 10 the court stayed the order at the companies' request, and the companies have appealed to the Seventh Circuit, where the motion for a stay pending appeal remains pending. Shareholders face uncertainty over dividends and buybacks while the appeal is pending, and the filing states the separation itself was not affected.
Litigation commenced October 1, 2026 in the U.S. District Court for the Southern District of Indiana by 15 states and one sovereign
Temporary restraining order issued October 9, 2026 would have barred dividends and share repurchases absent a court order
On October 10, 2026 the court stayed the order; the companies filed an appeal and motion with the Seventh Circuit, both still pending
The separation of Corteva and Vylor was completed October 1, 2026, and the filing says the order does not affect it
ADC Therapeutics agreed on October 7, 2026 to sell equity in an $86.6 million private placement, with closing expected October 22, 2026. The company also amended its term loan, cutting principal to $50.0 million, and amended its HealthCare Royalty agreement, removing a $150 million change-of-control payment. The filing gives preliminary third-quarter ZYNLONTA net product revenue of about $21.0 million and cash of $189.2 million, and the new share sales and warrant repricing add dilution for existing shareholders.
Private placement of 12,911,347 common shares at $1.42 per share, plus pre-funded warrants for 48,088,653 shares, expected to close October 22, 2026
Term loan prepayment of $70.0 million leaves $50.0 million outstanding; minimum liquidity covenant eliminated and a $65.0 million ZYNLONTA sales covenant set for the quarter ending December 31, 2026
HCR amendment removes the $150 million change-of-control payment and lets the company buy out royalties for $525 million by December 31, 2029 or $750 million from January 1, 2030
Preliminary Q3 2026 ZYNLONTA net product revenue of about $21.0 million; cash and equivalents of $189.2 million as of September 30, 2026
Nurix Therapeutics reported results for the fiscal quarter ended August 31, 2026. Total revenue rose to $673.1 million from $7.9 million a year earlier, mainly from $653.2 million of license revenue tied to the Roche collaboration, and the company reported net income of $549.8 million, or $4.73 per diluted share, compared with a net loss of $86.4 million a year earlier. Because most of the revenue came from a single license payment, the filing's profit figures are driven by that item rather than by recurring sales.
Total revenue was $673.1 million, versus $7.9 million a year earlier, including $653.2 million of Roche license revenue.
Net income was $549.8 million, or $4.73 per diluted share, versus a net loss of $86.4 million, or $1.03 per share, a year earlier.
General and administrative expenses rose to $34.4 million from $13.2 million, mainly due to one-time Roche transaction costs.
Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, versus $592.9 million on November 30, 2025.
UnitedHealth Group reported third quarter 2026 diluted earnings of $4.56 per share, up from $2.59 a year earlier, on revenues of $112.7 billion, down slightly from $113.2 billion. The company raised its full-year 2026 outlook to at least $20.50 per share in adjusted earnings, which matters to shareholders because profit rose while the outlook improved.
Diluted EPS was $4.56 versus $2.59 in Q3 2025; adjusted EPS was $4.69 versus $2.92.
Earnings from operations were $6.6 billion versus $4.3 billion; revenues were $112.7 billion versus $113.2 billion.
Full-year 2026 outlook: at least $19.50 per share in diluted earnings and at least $20.50 per share in adjusted earnings.
Medical care ratio was 88.4% versus 89.9% a year earlier; debt-to-capital ratio was 41.7% as of September 30, 2026.
On October 9, 2026, Co-Diagnostics entered a Loan Agreement with J.J. Astor & Co. for up to $3.1 million, with an initial $2.1 million funded at closing against a note with an original principal of $2.835 million. The notes are secured by substantially all company and subsidiary assets, are payable in 30 weekly installments, and can be converted into common stock at a discount to market, which could dilute existing shareholders; ATM sale proceeds are also routed to the lender.
Initial loan funded: $2.1 million; initial note original principal: $2.835 million; net initial proceeds about $2.016 million after a 4% origination fee
Conversion price is the greater of 90% of the lowest 10-day VWAP and the Nasdaq-based floor, with 600,000 commitment shares issued to the lender
Initial $1.0 million of ATM net proceeds is payable to the lender, with 80% of later net proceeds applied to the notes
Placement agent Maxim Group LLC receives a 5.0% cash fee on gross proceeds; a 19% default interest rate applies after an event of default
Brent Saunders left his roles as Bausch + Lomb chief executive and board member, effective October 12, 2026, under a mutually agreed separation. Thomas J. Appio, the board chairman who also serves as CEO of parent Bausch Health, was named interim CEO. The company said it expects to raise its full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D, based on preliminary third-quarter results.
Saunders' separation agreement provides a $75.5 million lump-sum cash payment and up to $50,000 in attorneys' fees, subject to a release of claims.
All of Saunders' outstanding equity awards, vested or unvested, were forfeited and cancelled.
Appio serves as interim CEO while remaining CEO of Bausch Health, the company's controlling shareholder.
The company expects to raise full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D; details are due with third-quarter results on October 28.
SSR Mining filed an updated Technical Report Summary for its Marigold Complex in Nevada, with an effective date of May 1, 2026, and a signature date of October 9, 2026. The report puts total Marigold mineral reserves at 3.96 million ounces of gold, which the filing says is a 73% increase in contained gold over previous estimates, driven by a $2,200 per ounce gold price assumption. The report also notes that Buffalo Valley mining operations are currently unpermitted and depend on permits being secured before planned production begins in 2029.
Marigold Probable Reserves of 240.44 million tonnes grading 0.46 g/t Au, containing 3.52 million ounces; total reserves including stockpiles and leach pad inventory are 3.96 million ounces
The filing says the updated $2,200 per ounce gold price assumption triggered a 73% increase in contained gold versus previous estimates
Buffalo Valley contributes 45.33 million tonnes of Probable Reserves containing 0.67 million ounces, but mining there is currently unpermitted and production is scheduled to begin in 2029
SS Innovations International entered a Securities Purchase Agreement on October 9, 2026, issuing a secured convertible promissory note with a $21,025,000 principal amount for a $20,000,000 purchase price. The note bears 8.75% interest, matures 36 months after closing, and is secured by the company's intellectual property and most subsidiary assets, which could dilute existing shareholders through conversions.
Note issued October 9, 2026 with $21,025,000 principal for a $20,000,000 purchase price, including $1,000,000 original issue discount and $25,000 investor expenses
Interest at 8.75% per annum compounded daily; matures 36 months after the Closing Date
Investor may convert at 95% of Market Price beginning on the Effective Date; company reserved an initial 8,000,000 common shares for conversions
Note secured by company IP held by SSI IP Holdings and assets of the company and SS IP; Indian subsidiary SSI-India excluded from collateral
IonQ signed a merger agreement on October 9, 2026 to acquire all outstanding shares of Elisity, Inc., a Zero Trust security company, paying in IonQ common stock. The closing consideration is set at $1.15 billion, with up to $150 million more in earnout shares tied to Elisity revenue milestones through January 31, 2028. Shareholders will see new shares issued at closing, and the deal is expected to close in the fourth quarter of 2026, subject to regulatory approvals.
Closing consideration of $1,150,000,000 in IonQ shares, plus up to $150,000,000 in earnout shares based on Elisity revenue milestones from August 1, 2026 to January 31, 2028
Share price used for issuance is capped between $33.07 and $49.61 per share
Separate retention pool of RSUs valued at $100,000,000, vesting over four years
Expected to close in fourth quarter 2026; either party may terminate if closing has not occurred by January 7, 2027
Charter Communications said Executive Vice President and Chief Commercial Officer Adam Ray will no longer serve in that role, effective October 12, 2026. He will stay on in a non-executive advisory capacity through December 31, 2026, and receives severance and equity vesting terms tied to a termination without cause, subject to signing a separation agreement. The change removes a senior commercial executive, but the filing gives no successor or financial impact figures.
Adam Ray ceases to serve as EVP and Chief Commercial Officer effective October 12, 2026
Ray remains employed in a non-executive advisory role through December 31, 2026
Severance and benefits follow a termination without cause, subject to a separation and release agreement
Certain restricted stock units and stock options continue to vest over original periods; options exercisable up to 60 months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.